Evidence map›Paper›PMID 41050936›Full record

ArticleiScience2025

FTO inhibition attenuates renal fibrosis by downregulating ferroptosis activator ACSL4 and profibrotic factor TGFBI.

Dalin Zhang, Chun-Lung Chiu, Ru Wen, Zhengyuan Qiu, Fernando Garcia-Marques, Abel Bermudez, Man Zhao, Hongjuan Zhao, Scott J Dixon, Donna M Peehl and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dalin ZhangDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Chun-Lung ChiuDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ru WenDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Zhengyuan QiuDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Fernando Garcia-MarquesDepartment of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Abel BermudezDepartment of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Man ZhaoDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Hongjuan ZhaoDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Scott J DixonDepartment of Biology, Stanford University, Stanford, CA 94305, USA.
Donna M PeehlDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94305, USA.
Erinn B RankinDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Sharon PitteriDepartment of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
James D BrooksDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Funding

Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Maximilian Diehn, Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Stanford O'Brien Urology Research CenterU54DK130065 · NIDDK · STANFORD UNIVERSITY · PI JAMES D. BROOKS · 2021 to 2026
$8.3M
The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinomaR01CA272432 · NCI · STANFORD UNIVERSITY · PI Erinn B Rankin · 2023 to 2026
$1.8M
RNA markers of renal damage due to obstructionR01DK101736 · NIDDK · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2017
$712k
NCI NIH HHS P01 CA257907NCI NIH HHS R01 CA272432NIDDK NIH HHS R01 DK101736NIDDK NIH HHS U54 DK130065
6 · The paper itself

Abstract

Renal fibrosis (RF) is the main pathological feature and a potential therapeutic target of chronic kidney disease (CKD), a prevalent health problem causing a high economic burden to the health care system. Fat mass and obesity-associated (FTO) inhibition, either genetically or pharmacologically, significantly reduced collagen deposition, lipid peroxidation, and ferroptosis marker expression after unilateral ureteral obstruction (UUO) compared with sham-operated controls in mice. In murine and human kidney epithelial cells as well as in human embryonic stem cell-derived kidney organoids, FTO inhibition reduced erastin-induced ferroptosis by decreasing lipid peroxidation and reactive oxygen species production by downregulating the ferroptosis driver ACSL4. Moreover, FTO inhibition directly downregulated

Indexed as

Biological sciencesFibrosisImmunologyNephrology

Identifiers

PMID41050936
PMCPMC12494575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.